Latest Conference Articles

The study results were presented at the 2019 San Antonio Breast Cancer Symposium, held December 10 through 14.

Despite the fact that menopausal hormone therapy with estrogen plus progestin is frequently used, its influence on breast cancer incidence and mortality has been debated, with discordant findings from prospective observational studies compared with randomized clinical trials.

Peter Schmid, FRCP, MD, PhD, discusses the 5 most common immune-related side effects seen in breast cancer patients. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.

Although there is no standard of care therapy following second-line treatment for human epidermal growth receptor 2 (HER2)-positive breast cancer, there are a number of options being researched.

By identifying molecular alterations contributing to CDK4/6i resistance, researchers hope to better understand which patients with breast cancer will respond best to the therapy.

Patients with metastatic breast cancer (MBC) who received an oral formulation of the chemotherapy drug paclitaxel (Taxol) had a better response and survival and elss neuropathy than patients who received intravenous (IV) paclitaxel.

Tim Ulbrich, PharmD, co-founder and CEO of Your Financial Pharmacist, discusses some ways to invest in your career. This video was at the ASHP (American Society of Health-System Pharmacists) Midyear Clinical Meeting & Exhibition in Las Vegas.

Health care facilities are not immune from active shooter incidents, and pharmacists in these workplaces need to know how to respond, according to a session at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.

With the spike in vaping-related illnesses are at an all-time high, staying on top of the news and counseling patients properly are some ways that pharmacists can help fight the epidemic, according to a session at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

Investigators have established a genomic outline of the CDK4/6i resistance in patients with breast cancer, growing the potential for novel treatments to circumvent that resistance.

Cyclin-dependent kinase 4/6 inhibitors offer the potential to significantly improve outcomes for women with HR-positive, HER2-negative breast cancer.

The study results also show improved outcomes for patients with brain metastases.

Megan Maroney, PharmD, BCPP, clinical associate professor, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey; clinical psychiatric pharmacist, Monmouth Medical Center, Long Branch, NJ, discusses suicidal ideation and behavior, and depression, as potential adverse effects of some medications.

Although CDK4/6 inhibitors prolong progression-free survival for patients with estrogen receptor-positive breast cancer, the ideal treatment for each patient is currently unclear until adverse effects appear.

The research presented at the 2019 San Antonio Breast Cancer Symposium suggests that the different mechanisms could be exploited to overcome CDK4/6 inhibitor resistance in breast cancer patients.

Jeffrey Fudin, PharmD, DAIPM, FASHP, FFSMB, discusses the role pharmacists play in the opioid crisis and pain management. This video was filmed at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas.

Researchers say several key questions remain in the treatment of breast cancer: whether CDK4/6i therapy should be continued beyond progression, what the mechanisms of resistance are, and how agents should be selected.

"I think immunotherapy has certainly arrived for breast cancer," said Rita Nanda, MD.

Research presented at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas showed that patients who received focused attention from pharmacists during hospital stays expressed higher satisfaction.

The award is in recognition of members David F. Chen, senior director of the Section of Pharmacy Practice Leaders, and Verna L. Reed, director of Customer Relations and Materials Management for their exemplary work within the organization.

Emmy-award winning actress Julia Louis-Dreyfus brought the huge crowd to its feet Wednesday at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada, during a conversation with Caleb McEwen, artistic director of the Brave New Workshop comedy theater in Minneapolis, Minnesota.

Krutika Mediwala, PharmD, BCPS, explains current best practices for health systems in antimicrobial stewardship. This video was filmed at the 2019 ASHP 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

Patricia Spears discusses what clinical trials can offer and when to start discussing them with patients. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

Tom Kraus, vice president, government affairs for the American Society of Health-System Pharmacists (ASHP) discusses legislators' top concerns with drug pricing and what they're doing to solve the problem. This video was filmed at the ASHP 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.

The consumption of these antibiotics may lead to dangerous unintended consequences, such as adverse effects that include treatment failures, and antibiotic drug resistance.

Volunteer leaders recognized for advancing mission of sections, new practitioners forum.

Danny Sanchez, VP and general manager of population health services for Omnicell, discusses how technology is bringing pharmacists closer to their patients. This video was filmed at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas.

Immunotherapy drug blinatumomab showed benefit in pediatric patients with relapsed acute lymphoblastic leukemia who have minimal residual disease following chemotherapy.

A combination therapy of carfilzomib, dexamethasone, and daratumumab extended progression-free survival when compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

An oral formulation of azacitidine improved overall survival in patients with acute myeloid leukemia in first remission.